MADRID, Spain, June 26, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing of the first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/1451R_1-2020-6-25.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Contacts:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com